natgillin/translations-raw huggingface dataset:
ADCS-IADL score: En positiv forskel i DLSM indikerer større forbedring med Prometax 15 cm2 sammenlignet med Prometax 10 cm2.
ADCS-IADL scores: A positive difference in DLSM indicates greater improvement in Prometax 15 cm2 as compared to Prometax 10 cm2.
ADCS-IADL score: En positiv forskel i DLSM indikerer større forbedring med rivastigmin 15 cm2 sammenlignet med rivastigmin 10 cm2.
ADCS-IADL scores: A positive difference in DLSM indicates greater improvement in Rivastigmine
Addisons sygdom (en sygdom i binyrerne, der medfører mangel på visse hormoner),
Addison’s disease (a disorder of the adrenal glands causing a lack of some hormones)
Addisons sygdom)
Addison’s disease)
Additive til synergistiske virkninger observeredes i kombinationsstudier med proteasehæmmere og med nukleosid- og non-nukleosid-analoghæmmere af hiv-reverstranskriptase.
Additive to synergistic effects were observed in combination studies with protease inhibitors, and with nucleoside and non-nucleoside analogue inhibitors of HIV reverse transcriptase.
Addmedica,
Addmedica
Addmedica, 101 rue Saint Lazare – 75009 París - Francia
Addmedica, 101 rue Saint Lazare – 75009 Paris - France
Adefovir er aktiv mod hepadnavirus in vitro, herunder alle almindelige former for lamivudin-resistent HBV (rtL180M, rtM204I, rtM204V, rtL180M/rtM204V), famciclovirforbundne mutationer (rtV173L, rtP177L, rtL180M, rtT184S eller rtV207I) og hepatitis B immunoglobulin kvitterede mutationer (rtT128N og rtW153Q) samt i in vivo-dyremodeller af hepadnavirusreplikation.
Adefovir is active against hepadnaviruses in vitro, including all common forms of lamivudine- resistant HBV (rtL180M, rtM204I, rtM204V, rtL180M/rtM204V), famciclovir-associated mutations (rtV173L, rtP177L, rtL180M, rtT184S or rtV207I) and hepatitis B immunoglobulin escape mutations (rtT128N and rtW153Q), and in in vivo animal models of hepadnavirus replication.
Adefovir og Viramune kan co- administreres uden dosisjustering.
Adefovir and Viramune may be coadministered without dose adjustments.
Adefovir tilhører en gruppe af antivirale stoffer, der kaldes nukleotidanaloger.
Adefovir is an antiviral belonging to the class ‘nucleoside analogues’.
Adefovirdiphosphat har en intracellulær halveringstid på 12 til 36 timer i aktive og hvilende lymfocytter.
Adefovir diphosphate has an intracellular half-life of 12 to 36 hours in activated and resting lymphocytes.
Adefovirdiphosphat hæmmer selektivt HBV-dna- polymeraser ved koncentrationer, som er 12, 700 og 10 gange lavere end dem, som er nødvendige for at hæmme humane dna-polymeraser, hhv. α, β og γ.
Adefovir diphosphate selectively inhibits HBV DNA polymerases at concentrations 12-, 700-, and 10-fold lower than those needed to inhibit human DNA polymerases α, β, and γ, respectively.
Adefovirdipivoxil bør ikke tages samtidig med tenofovirdisoproxilfumarat (Viread).
Adefovir dipivoxil should not be administered concurrently with tenofovir disoproxil fumarate (Viread).
Ademhalingsstelsel-, borstkas- en mediastinumaandoeningen
Respiratory, thoracic and mediastinal disorders
Adempas 0,5 mg filmovertrukket tablet
Adempas 0.5 mg film-coated tablets
Adempas 0,5 mg filmovertrukne tabletter Adempas 1 mg filmovertrukne tabletter Adempas 1,5 mg filmovertrukne tabletter Adempas 2 mg filmovertrukne tabletter Adempas 2,5 mg filmovertrukne tabletter
Adempas 0.5 mg film-coated tablets Adempas 1 mg film-coated tablets Adempas 1.5 mg film-coated tablets Adempas 2 mg film-coated tablets Adempas 2.5 mg film-coated tablets
Adempas 0,5 mg – pakning med 42 filmovertrukne tabletter - EU/1/13/907/001 Adempas 0,5 mg – pakning med 84 filmovertrukne tabletter - EU/1/13/907/002 Adempas 0,5 mg – pakning med 90 filmovertrukne tabletter - EU/1/13/907/003 Adempas 0,5 mg – pakning med 294 filmovertrukne tabletter - EU/1/13/907/016 Adempas 1 mg – pakning med 42 filmovertrukne tabletter - EU/1/13/907/004 Adempas 1 mg – pakning med 84 filmovertrukne tabletter - EU/1/13/907/005 Adempas 1 mg – pakning med 90 filmovertrukne tabletter - EU/1/13/907/006 Adempas 1 mg – pakning med 294 filmovertrukne tabletter - EU/1/13/907/017 Adempas 1,5 mg – pakning med 42 filmovertrukne tabletter - EU/1/13/907/007 Adempas 1,5 mg – pakning med 84 filmovertrukne tabletter - EU/1/13/907/008 Adempas 1,5 mg – pakning med 90 filmovertrukne tabletter - EU/1/13/907/009 Adempas 1,5 mg – pakning med 294 filmovertrukne tabletter - EU/1/13/907/018 Adempas 2 mg – pakning med 42 filmovertrukne tabletter - EU/1/13/907/010 Adempas 2 mg – pakning med 84 filmovertrukne tabletter - EU//13/907/011 Adempas 2 mg – pakning med 90 filmovertrukne tabletter - EU/1/13/907/012 Adempas 2 mg – pakning med 294 filmovertrukne tabletter - EU/1/13/907/019 Adempas 2,5 mg – pakning med 42 filmovertrukne tabletter - EU/1/13/907/013 Adempas 2,5 mg – pakning med 84 filmovertrukne tabletter - EU1/13/907/014 Adempas 2,5 mg – pakning med 90 filmovertrukne tabletter - EU/1/13/907/015 Adempas 2,5 mg – pakning med 294 filmovertrukne tabletter - EU/1/13/907/020
Adempas 0.5 mg – pack of 42 film-coated tablets - EU/1/13/907/001 Adempas 0.5 mg – pack of 84 film-coated tablets - EU/1/13/907/002 Adempas 0.5 mg – pack of 90 film-coated tablets - EU/1/13/907/003 Adempas 0.5 mg – pack of 294 film-coated tablets - EU/1/13/907/016 Adempas 1 mg – pack of 42 film-coated tablets - EU/1/13/907/004 Adempas 1 mg – pack of 84 film-coated tablets - EU/1/13/907/005 Adempas 1 mg – pack of 90 film-coated tablets - EU/1/13/907/006 Adempas 1 mg – pack of 294 film-coated tablets - EU/1/13/907/017 Adempas 1.5 mg – pack of 42 film-coated tablets - EU/1/13/907/007 Adempas 1.5 mg – pack of 84 film-coated tablets - EU/1/13/907/008 Adempas 1.5 mg – pack of 90 film-coated tablets - EU/1/13/907/009 Adempas 1.5 mg – pack of 294 film-coated tablets - EU/1/13/907/018 Adempas 2 mg – pack of 42 film-coated tablets - EU/1/13/907/010 Adempas 2 mg – pack of 84 film-coated tablets - EU/1/13/907/011 Adempas 2 mg – pack of 90 film-coated tablets - EU/1/13/907/012 Adempas 2 mg – pack of 294 film-coated tablets - EU/1/13/907/019 Adempas 2.5 mg – pack of 42 film-coated tablets - EU/1/13/907/013 Adempas 2.5 mg – pack of 84 film-coated tablets - EU/1/13/907/014 Adempas 2.5 mg – pack of 90 film-coated tablets - EU/1/13/907/015 Adempas 2.5 mg – pack of 294 film-coated tablets - EU/1/13/907/020
Adempas 0,5 mg, 1 mg, 1,5 mg, 2 mg eller 2,5 mg
Adempas 0.5 mg, 1 mg, 1.5 mg, 2 mg or 2.5 mg
Adempas 1 mg filmovertrukket tablet
Adempas 1 mg film-coated tablets
Adempas 1,5 mg filmovertrukket tablet
Adempas 1.5 mg film-coated tablets
Adempas 2 mg filmovertrukket tablet
Adempas 2 mg film-coated tablets
Adempas 2,5 mg filmovertrukket tablet
Adempas 2.5 mg film-coated tablets
Adempas blev sammenlignet med placebo (virkningsløs behandling) i én hovedundersøgelse hos 262 patienter med CTEPH, der ikke kunne opereres, eller med vedvarende eller tilbagevendende CTEPH efter operation.
Adempas was compared with placebo (a dummy treatment) in one main study in 262 patients with CTEPH who could not be operated, or in whom CTEPH remained or returned after surgery.
Adempas er et lægemiddel, der indeholder det aktive stof riociguat.
Adempas is a medicine that contains the active substance riociguat.
Adempas er påvist at være effektivt til at forbedre den distance, som patienter med CTEPH eller PAH kan gå på 6 minutter (anvendes som mål for den fysiske kapacitet):
Adempas has been shown to be effective at improving the distance patients with CTEPH or PAH could walk in six minutes (a way of measuring exercise capacity):
Adempas er, som monoterapi eller i kombination med endothelin-receptorantagonister, indiceret til behandling af voksne patienter med pulmonal arteriel hypertension (PAH ) med WHO-funktionsklasse (FC) II til III for at forbedre deres fysiske arbejdsevne.
Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity.
Adempas fås kun på recept, og behandlingen bør kun iværksættes og overvåges af en læge med erfaring i behandling af CTEPH eller PAH.
Adempas can only be obtained with a prescription and treatment should only be started and monitored by a doctor who has experience in the treatment of CTEPH or PAH.
Adempas kan anvendes alene eller kombineret med andre lægemidler mod PAH (endothelin-receptorantagonister).
Adempas can be used on its own or in combination with other medicines for PAH called ‘endothelin receptor antagonists’.
Adempas leveres som tabletter i styrkerne 0,5, 1, 1,5, 2 og 2,5 mg.
Adempas is available as tablets (0.5, 1, 1.5, 2 and 2.5 mg).
Adempas må ikke anvendes hos patienter, der har svært nedsat leverfunktion, eller hos hvem blodtrykket under hjertets sammentrækning (det systoliske blodtryk) er under 95 mmHg før påbegyndelse af behandlingen, eller som er gravide.
Adempas must not be used in patients with severely reduced liver function, with systolic blood pressure (blood pressure when the heart is contracting) below 95 mmHg before starting treatment, or during pregnancy.
Adempas, som monoterapi eller i kombination med endothelin-receptorantagonister, er indiceret til behandling af voksne patienter med pulmonal arteriel hypertension (PAH) med WHO-funktionsklasse (FC) II til III for at forbedre deres fysiske arbejdsevne.
Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity.
Además de la correlación inconstante entre la reducción de la tasa de crisis y el aumento de la HbF, el efecto citorreductor de hidroxicarbamida, sobre todo el descenso del número de neutrófilos, fue el factor más estrechamente relacionado con la reducción de la tasa de crisis.
Beside the inconstant correlation between reduction of crisis rate and the increase in HbF, the cytoreductive effect of hydroxycarbamide, particularly the drop of neutrophils, was the factor with the strongest correlation to a reduced crisis rate.
Además la hidroxicarbamida produce una inhibición inmediata de la síntesis de ADN actuando como inhibidor de la ribonucleótido reductasa, sin interferir en la síntesis del ácido ribonucleico ni de las proteínas.
In addition hydroxycarbamide causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or protein.
adenopati
thy
Adenosinreceptoragonister, herunder Rapiscan, inducerer arteriel vasodilatation og hypotension.
Adenosine receptor agonists, including Rapiscan induce arterial vasodilation and hypotension.
Adenosinreceptoragonister, herunder Rapiscan, kan undertrykke sinusknuden og AV-knuden og forårsage 1., 2. eller 3. grads AV-blok eller sinusbradykardi, som kræver behandling.
Adenosine receptor agonists, including Rapiscan, can depress the SA and AV nodes and may cause first, second or third degree AV block, or sinus bradycardia requiring intervention.
ADENURIC 120 mg filmovertrukne tabletter
ADENURIC 120 mg film-coated tablets
ADENURIC 120 mg filmovertrukne tabletter Febuxostatum
ADENURIC 120 mg film-coated tablets Febuxostat
ADENURIC 120 mg tabletter Febuxostatum
ADENURIC 120 mg tablets Febuxostat
ADENURIC 80 mg filmovertrukne tabletter
ADENURIC 80 mg film-coated tablets
ADENURIC 80 mg filmovertrukne tabletter ADENURIC 120 mg filmovertrukne tabletter Febuxostat
ADENURIC 80 mg film-coated tablets ADENURIC 120 mg film-coated tablets Febuxostat
ADENURIC 80 mg filmovertrukne tabletter Febuxostatum
ADENURIC 80 mg film-coated tablets Febuxostat
ADENURIC 80 mg leveres i pakninger med 14, 28, 42, 56, 84 eller 98 filmovertrukne tabletter.
ADENURIC 80 mg and 120 mg is available in packs containing 14, 28, 42, 56, 84 and 98 film-coated tablets.
ADENURIC 80 mg tabletter Febuxostatum
ADENURIC 80 mg tablets Febuxostat
Adenuric anvendes til behandling af voksne med langvarig hyperurikæmi (et højt indhold af urinsyre eller ”urat” i blodet).
Adenuric is used to treat adults with long-term hyperuricaemia (high levels of uric acid or ‘urate’ in the blood).
Adenuric anvendes til patienter, som allerede har symptomer på opbygning af krystaller, herunder arthrose (smerter og inflammation i leddene) eller tophi (”sten”, større aflejringer af uratkrystaller, som kan medføre led- og knogleskader).
Adenuric is used in patients who already have signs of a build-up of crystals, including gouty arthritis (pain and inflammation in the joints) or tophi (‘stones’, larger deposits of urate crystals that can cause joint and bone damage).
ADENURIC bør ikke anvendes under graviditet.
ADENURIC should not be used during pregnancy.
ADENURIC er til oral anvendelse og kan tages alene eller i forbindelse med et måltid.
ADENURIC should be taken by mouth and can be taken with or without food.
ADENURIC virker tilstrækkeligt hurtigt til, at serumurinsyren kan testes igen efter to uger.
ADENURIC works sufficiently quickly to allow retesting of the serum uric acid after 2 weeks.
Adfærdsforstyrrelser, depressiv stemning, følelsesmæssige forstyrrelser, angst, mareridt
Abnormal behaviour, depressed mood, emotional disorder, fear, nightmare
Adfærdsmæssige forandringer, som ændring af hundens aktivitetsniveau eller en mere social adfærd, er almindelige.
Behavioural changes such as modification of dog’s activity or more social behaviour are common.
Adfærdsmæssige ændringer, herunder psykomotorisk hyperaktivitet og irritabilitet (især hos børn)
Behavioural changes, including psychomotor hyperactivity and irritability (predominantly in children)
Adfærdsændringer, såsom usædvanligt højt aktivitetsniveau og irritabilitet (selvom disse bivirkninger primært opstår hos børn, når de får denne lægemiddelkombination i en lavere styrke).
Behavioural changes, such as being unusually active and irritable (although these effects occur mainly in children when prescribed this combination of drugs but in a lower strength).
Adfærdsændringer, særligt hos børn.
Changes in behaviour, especially in children.
adhesiner F4 (F4ab, F4ac,
adhesins F4 (F4ab, F4ac,
Adhesiner F4, (F4ab, F4ac, F4ad), F5, F6,F41 Aluminium adjuvans.
adhesins: F4 (F4ab, F4ac, F4ad), F5, F6, F41 Aluminium adjuvant
Adipocytisk sarkom (alle undertyper), alle rabdomyosarkomer, som ikke var alveolære eller pleomorfe, kondrosarkom, osteosarkom, Ewing tumorer/primitive neuroektodermale tumorer (PNET), GIST, dermatofibrosarkoma protuberans, inflammatorisk myofibroblastisk sarkom, malignt mesoteliom og blandede mesodermale uterustumorer.
Adipocytic sarcoma (all subtypes), all rhabdomyosarcoma that were not alveolar or pleomorphic, chondrosarcoma, osteosarcoma, Ewing tumours/Primitive neuroectodermal tumours (PNET), GIST, dermofibromatosis sarcoma protuberans, inflammatory myofibroblastic sarcoma, malignant mesothelioma and mixed mesodermal tumours of the uterus.
Adipositas
Obesity
Adipositas:
Obesity:
Adipøs 30-
Obese 30
Adipøse patienter er i højere risiko for tromboemboli.
Obese patients are at higher risk for thromboembolism.
Adipøse patienter har en højere risiko for tromboemboli.
Obese patients are at higher risk for thromboembolism.
aDiskrete noduli vil modtage en initial lysbehandling på 50 J/cm (ved hjælp af kort diffusor) inden behandlingen med ballonlys.
aDiscrete nodules will receive an initial light application of 50 J/cm (using short diffuser) before the balloon light application.
aDiskrete noduli vil modtage en initial lysbehandling på 50 J/cm (ved hjælp af kort diffusor) inden behandlingen med ballonlys.
aDiscrete nodules will receive an initial light application of 50 J/cm (using short diffuser) before the balloon light application.‌
aDisse kriterier opfylder National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition på ≥CTC grad 2 blødning.
a These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of ≥ CTC Grade 2 bleeding
aDisse kriterier opfylder National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition på ≥CTC grad 2 blødning.
a These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of ≥ CTC Grade 2 bleeding.
aDisse kriterier opfylder National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition på ≥CTC grad 2 blødning.
a These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of ≥CTC Grade 2 bleeding
aDisse kriterier opfylder National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition på ≥CTC grad 2 blødning.
a These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of ≥CTC Grade 2 bleeding.
Adjupanrix er en vaccine til beskyttelse af voksne mod ‘pandemisk’ influenza.
Adjupanrix is a vaccine for use in adults to protect against ‘pandemic’ flu.
Adjupanrix er en vaccine, som anvendes til voksne i alderen fra 18 år mod influenza ved udbrud af en pandemi.
Adjupanrix is a vaccine for use in adults from 18 years old to prevent pandemic flu (influenza).
Adjupanrix er en ‘mockup’-vaccine.
Adjupanrix is a ‘mock-up’ vaccine.
Adjupanrix indeholder thiomersal som konserveringsmiddel. og det er muligt, at du kan opleve en overfølsomhedsreaktion.
Adjupanrix contains thiomersal as a preservative and it is possible that you may experience an allergic reaction.
Adjupanrix suspension og emulsion til injektionsvæske, emulsion
Adjupanrix suspension and emulsion for emulsion for injection
Adjupanrix, suspension og emulsion til injektionsvæske, emulsion.
Adjupanrix suspension and emulsion for emulsion for injection.
Adjuvans (Adjuvanser):
Adjuvants:
Adjuvans (i solvensen) 250 (225-275) µg saponin
Adjuvant (in the solvent) 250 (225-275) μg saponin
Adjuvans bruges for at få kroppen til at danne et bedre immunforsvar (en bedre forsvarsmekanisme) over for vaccinen.
Adjuvants are used to improve the body’s response to the vaccine.
Adjuvans bruges for at få kroppen til at reagere bedre på vaccinen.
Adjuvants are used to improve the body’s response to the vaccine.
Adjuvans bruges til at øge kroppens immunforsvar mod vaccinen.
Adjuvants are used to improve the body’s response to the vaccine.
Adjuvans dl--tocopherolacetat 150 mg
Adjuvant: dl-α-tocopherol acetate 150 mg
Adjuvans MF59C.1 indeholdende:
Adjuvant MF59C.1 containing:
Adjuvans MF59C.1, som indeholder:
Adjuvant MF59C.1 containing:
Adjuvans MF59C.1, som indeholder: squalen 9,75 milligram
Adjuvant MF59C.1 containing:
Adjuvans til HUMENZA injektionsvæske, emulsion
Adjuvant for HUMENZA emulsion for injection
Adjuvans til HUMENZA injektionsvæske, emulsion IM
Adjuvant for HUMENZA emulsion for injection IM
Adjuvans, emulsion til Arepanrix i.m.
Adjuvant emulsion for Arepanrix I.M.
Adjuvans, emulsion til injektionsvæske 25 hætteglas: emulsion
Adjuvant emulsion for injection 25 vials: emulsion
Adjuvans, emulsion til Pandemrix i.m.
Adjuvant emulsion for Pandemrix I.M.
Adjuvans, emulsion til Prepandrix i.m.
Adjuvant emulsion for Prepandrix I.M.
Adjuvans, emulsion til Pumarix i.m.
Adjuvant emulsion for Pumarix I.M.
Adjuvans:
A/Vietnam/1194/2004 (H5N1)
Adjuvans: 250 (225-275) µg saponin (fra solvensen).
Adjuvant: 250 (225-275) μg saponin (from the solvent)
Adjuvans: dl--tocopherolacetat 150 mg
Adjuvant: dl-α-tocopherol acetate 150 mg
Adjuvans: MF59C.1 olie-i-vand-emulsion indeholdende squalen som oliefase-stabiliseret med polysorbat 80 og sorbitantrioleat i en citratbuffer.
Adjuvant: MF59C.1 oil in water emulsion containing squalene, as the oil phase, stabilised with polysorbate 80 and sorbitan trioleate in a citrate buffer.
Adjuvans: MF59C.1-olie bestående af squalen, polysorbat 80 og sorbitantrioleat.
Adjuvant: MF59C.1 oil composed of squalene, polysorbate 80 and sorbitan trioleate.
Adjuvans: Paraffinolie, tynd Sorbitansesquioleat Polysorbat 80
Sorbitan sesquioleate Polysorbate 80
adjuvans: tynd paraffin olie............................................................................................
adjuvant: light paraffin oil ...........................................................................................
Adjuvansen består af squalen (10,69 mg), DL-α-tocopherol (11,86 mg) og polysorbat 80 (4,86 mg).
This adjuvant contains squalene (10.69 milligrams), DL--tocopherol (11.86 milligrams) and polysorbate 80 (4.86 milligrams)
Adjuvansen består af squalen (10,69 mg), DL-α-tocopherol (11,86 mg) og polysorbat 80 (4,86 mg).
This adjuvant contains squalene (10.69 milligrams), DL--tocopherol (11.86 milligrams) and polysorbate 80 (4.86 milligrams).
Adjuvansen er en hvid, uklar emulsion.
The adjuvant is a white opaque emulsion.
Adjuvanser:
Adjuvants
Adjuvanser: Aluminiumhydroxid Saponin
Adjuvants: Aluminium hydroxide Saponin
Adjuvanser: aluminiumhydroxid, saponin Opaliserende pink med genoprysteligt sediment.
Opalescent pink with resuspendable sediment.
Adjuvanset indeholder også polysorbat 80 og sorbitantrioleat i en citratbuffer.
The adjuvant includes also polysorbate 80 and sorbitan trioleate in a citrate buffer.
Adjuverende behandling med Docefrez 75 mg/m² i kombination med doxorubicin og cyclophosphamid hos patienter med lymfeknude-positiv (TAX 316) og lymfeknude-negativ (GEICAM 9805) brystkræft – pooled data:
Adjuvant therapy with Docetaxel 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer - pooled data
Adjuverende monoterapi med capecitabin ved kolonkræft
Monotherapy with capecitabine in adjuvant colon cancer
Adjuverende stråleterapi blev givet i henhold til eksisterende vejledninger på de deltagende centre og blev givet til 69 % af patienterne, som fik TAC, og 72 % af patienterne som fik FAC.
Adjuvant radiation therapy was administered according to guidelines in place at participating institutions and was given to 57.3% of patients who received TAC and 51.2% of patients who received FAC.
adjuveret)
adjuvanted)
Admininstration
Method of administration
administartionsstedet
conditions
ADMINISTATIONSMETODE
METHOD OF ADMINISTRATION
administeret sammen med
co- administered with 300 mg
Administr ation
Route of administ- ration
administra-
induration
Administra- tionsmåde
Route of administration
administra- tionsstedet
eruption
Administra- tionsvej
Route of Administration
Administrat ion
Route of administration
Administrati on
Route of administration
Administrati on Intravenøs
Route of administration
administratio
disorders
Administratio n
Route of Administration
Administration
(concentration)
Administration
Blood pressure
administration
condition
Administration
EU/1/14/988/001
Administration
Method of administration Oral use.
administration
route
Administration
Route of
Administration (indgivelse)
Method of administration
Administration (intravenøs infusion):
Administration (Intravenous Infusion):
Administration (primær forebyggelse af VTE ved ortopædkirurgi)
Method of administration (pVTEp orthopaedic surgery)
Administration (primær forebyggelse af VTE ved ortopædkirurgi, SPAF, DVT/LE)
Method of administration ( pVTEp orthopaedic surgery , SPAF, DVT/PE)
Administration (SPAF, DVT/LE)
Method of administration (SPAF, DVT/PE)
administration af
administration with
administration af
regarding co-administration of
Administration af 0,5 mg entecavir med et fedtrigt standardmåltid (945 kcal, 54,6 g fedt) eller et let måltid (379 kcal, 8,2 g fedt) forårsagede en minimal forsinkelse i absorption (1 - 1,5 time efter fødeindtagelse vs.
Administration of 0.5 mg entecavir with a standard high-fat meal (945 kcal, 54.6 g fat) or a light meal (379 kcal, 8.2 g fat) resulted in a minimal delay in absorption (1-1.5 hour fed vs.
Administration af 100 mg oseltamivirphosphat to gange daglig i fem dage til patienter med varierende grad af nedsat nyrefunktion har vist at eksponeringen over for oseltamivircarboxylat er omvendt proportional med faldende nyrefunktion.
Administration of 100 mg oseltamivir phosphate twice daily for 5 days to patients with various degrees of renal impairment showed that exposure to oseltamivir carboxylate is inversely proportional to declining renal function.